



**Formulary Updates
May-June 2019**

CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis. All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.

Drug	Class	Formulary Status	Additional Information	Implementation Date
Formulary Additions/Deletions				
Rasuvo Injection	Anti-arthritis agent	Formulary	Restriction: Quantity Limit #4/28-DS	5/1/2019
Advair Diskus (generic)	Inhaled Corticosteroid/Long-Acting-Beta-Agonist	Formulary	Restrictions: Quantity Limit of # 1 inhaler/30-DS, all other restrictions were removed	5/1/2019
Otrexup Injection	Anti-arthritis agent	Non-Formulary	Removed from Formulary, preferred injectable methotrexate, Rasuvo	6/1/2019
Symbicort	Inhaled Corticosteroid/Long-Acting-Beta-Agonist	Non-Formulary	Removed from Formulary, preferred ICS/LABA Advair Diskus or AirDuo Respiclick	6/1/2019
Breo Ellipta	Inhaled Corticosteroid/Long-Acting-Beta-Agonist	Non-Formulary	Removed from Formulary, preferred ICS/LABA Advair Diskus or AirDuo Respiclick	6/1/2019